Ovid Therapeutc (OVID) Posts Earnings Results, Misses Expectations By $0.09 EPS
Ovid Therapeutc (NASDAQ:OVID) released its quarterly earnings results on Thursday. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.48) by $0.09, Bloomberg Earnings reports.
Ovid Therapeutc (NASDAQ:OVID) traded up 4.70% on Friday, reaching $5.57. 50,654 shares of the company’s stock traded hands. The stock’s 50 day moving average is $9.14 and its 200 day moving average is $11.23. The firm’s market cap is $137.03 million. Ovid Therapeutc has a 52-week low of $5.28 and a 52-week high of $15.93.
COPYRIGHT VIOLATION NOTICE: This piece was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://www.americanbankingnews.com/2017/08/11/ovid-therapeutc-ovid-posts-earnings-results-misses-expectations-by-0-09-eps.html.
A number of equities research analysts have recently issued reports on the stock. JMP Securities assumed coverage on shares of Ovid Therapeutc in a report on Tuesday, May 30th. They set an “outperform” rating and a $26.00 price target on the stock. William Blair assumed coverage on shares of Ovid Therapeutc in a report on Tuesday, May 30th. They set an “outperform” rating on the stock. Citigroup Inc. assumed coverage on shares of Ovid Therapeutc in a report on Tuesday, May 30th. They set a “buy” rating and a $21.00 price target on the stock. Finally, Cowen and Company assumed coverage on shares of Ovid Therapeutc in a report on Tuesday, May 30th. They set an “outperform” rating on the stock.
Ovid Therapeutc Company Profile
Ovid Therapeutics Inc (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist.
Receive News & Ratings for Ovid Therapeutc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutc and related companies with MarketBeat.com's FREE daily email newsletter.